By HotStockRockets | Wednesday 29 July 2015
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
OptiBiotix Health (OPTI) has announced completion of clinical studies on its capsular food supplement to reduce cholesterol with no compliance or safety concerns raised. This is good news.
The 50 volunteer study commenced at the start of January and has completed as planned, allowing sample testing and data analysis to take place and reporting in September.
On re-recommending the shares at a 39p offer price a month ago we noted that the company was working in a very topical space and its emphasising that “as our development programmes progress and OptiBiotix is able to demonstrate product safety and efficacy, we anticipate increasing partner interest”. Indeed this has already been evident since our re-recommendation with two deals announced.
Having been hindered by a stock overhang, the shares had slipped; falling below 33p earlier this month. However, the latest news has further boosted the recovery since – with the shares now back up to around the 39p re-recommendation price.
We continue to view this as an unexpected opportunity at this stage and to target 47p to sell PDQ as the company continues to announce progress in its highly topical space.
At up to 40p the shares are a buy as we are confident that there will be more news showing a clear path to monetising this technology very soon.
This material first appeared on Hot Stock Rockets. Hot Stock Rockets will be serving up its next red hot share tip NEXT FRIDAY. To access the UK’s fastest growing share tipping website for less than £5 a month ( or for £5 for one month) click HERE
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |